Boehringer Ingelheim Licenses BaroFold's PreEMT High-Pressure Protein-Refolding Technology - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Boehringer Ingelheim Licenses BaroFold's PreEMT High-Pressure Protein-Refolding Technology


Pharmaceutical Technology Europe

Boehringer Ingelheim has entered into a non-exclusive technology and commercial license option agreement with BaroFold. Under the terms of the agreement, Boehringer Ingelheim will license BaroFold's pressure-enabled manufacturing technology (PreEMT). A laboratory-scale reactor of the PreEMT high-pressure protein-refolding technology will be installed at Boehringer Ingelheim's microbial facility in Vienna, Austria. The technology will be used for the development of biopharmaceutical production processes.

PreEMT uses high pressure to disaggregate and control the refolding of recombinant proteins to their native structures at yields and efficiencies that cannot be achieved with existing technologies. PreEMT can substantially reduce the cost of manufacturing because of its increased yield and throughput at high protein concentrations. The technology is readily scalable and has been used for the cGMP production of clinical materials for Phase I to Phase III trials.

Georg Klima, executive director of Process Science Austria at Boehringer Ingelheim, said in a press statement, "This collaboration builds upon the exciting work we have completed with BaroFold over the last 18 months and enhances our strategy to integrate the most innovative technologies for biologic manufacturing. We will be able to leverage BaroFold's high pressure refold technology on a variety of proteins under development at our facility in Vienna."

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
33%
Breakthrough designations
11%
Protecting the supply chain
39%
Expedited reviews of drug submissions
11%
More stakeholder involvement
6%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology Europe,
Click here